

English | Español

Home

Products

Contacts

About DOSA



(\*) Next launching



**Name of the product: MYCOLDOSA 250 (\*)**  
**Active ingredient: Mycophenolate mofetil**  
**Dosage form: hard capsules**



**Name of the product: MYCOLDOSA 500**  
**Active ingredient: Mycophenolate mofetil**  
**Dosage form: film-coated tablets**

Dispensing requirements: Rx only  
 Argentine Industry

**Composition:**

Each MYCOLDOSA 250 capsule contains mycophenolate mofetil 250 mg, povidone K90, sodium croscarmellose, pregelatinised starch, and magnesium stearate.

Each MYCOLDOSA 500 film-coated tablet contains mycophenolate mofetil 500 mg, povidone K90, sodium croscarmellose, microcrystalline cellulose PH 120, magnesium stearate, and OPADRY II 85G28725.

**Indications:**

MYCOLDOSA is indicated for the prevention of organ rejection following transplants, and for the treatment of resistant organ rejection in patients with kidney transplant. MYCOLDOSA must be concomitantly administered with cyclosporine and corticoids.

**Therapeutic action:**

Immunosuppressant.

**Storage:**

Keep between 15° and 30° C in the marketed packing.

**Marketed presentations:**

MYCOLDOSA 250:

Packs containing 10, 20, 30, 40, 50, 60 and 100 capsules.

Packs containing 250, 500 and 1000 capsules, for use in hospitals.

MYCOLDOSA 500:

Packs containing 10, 20, 30, 40, 50, 60 and 100 film-coated tablets.

Packs containing 250, 500 and 1000 film-coated tablets, for use in hospitals.

Medicinal speciality authorised by the Ministry of Health.

Certificate N° 52115

**Laboratorio DOSA S.A.**

**Girardot 1369, (C1427AKC) Buenos Aires, Argentine**

**Pharmaceutical Director: María C. Terzo, Pharmacist**

Laboratorio DOSA S.A. - Girardot 1369 (C1427AKC) Ciudad de Buenos Aires - Argentina